This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Corticosteroids (respiratory)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Inhaled steroids may be used in the longterm treatment of asthma and, occasionally, chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (1).

In asthma, airway inflammation is present even in mild disease, and therapy with inhaled glucocorticoids is now recommended at a much earlier stage than previously.

  • according to a number of clinical trials and studies, inhaled corticosteroids reduce hospitalization rates and death rates due to asthma (2)

Extensive studies have demonstrated that inhaled steroids, irrespective of the preparation, have minimal systemic effects when used at low doses. Systemic side effects may occur at high doses - above 400 microgrammes of beclomethasone per day in children and 800 microgrammes of beclomethasone in adults (3).

The amount of systemic absorption can be reduced by the use of spacer devices with metered-dose inhalers and by mouth rinsing after the use of dry-powder inhalers. These should be used whenever doses of 800 microgrammes of beclomethasone per day (or equivalent) or more are needed to control asthma.

Smoking (both current and ex-smokers) decreases the effect of inhaled steroids and higher doses may be needed in these patients (4).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.